Amarin Narrows Losses and Beats Adjusted EPS Expectations in Q4 2025
Amarin Corporation plc (NASDAQ:AMRN) reported its financial results for the fourth quarter and full year ended December 31, 2025, delivering a mixed picture of declining revenues but significantly improved profitability. The cardiovascular-focused pharmaceutical company's results highlight the ongoing impact of a major strategic restructuring and a shift towards a more partner-dependent international business model.
Earnings Snapshot: A Beat on Profitability
The core of the earnings story lies in the comparison between Amarin's reported figures and Wall Street's expectations. For the fourth quarter, the company's performance on the bottom line surpassed analyst forecasts.
- Revenue: Total net revenue was $49.2 million, a 21% decrease from the $62.3 million reported in Q4 2024. This figure came in below the analyst consensus estimate of approximately $51.6 million.
- Earnings Per Share (Non-GAAP): The company reported adjusted earnings per share (EPS) of $0.01. This result exceeded the analyst estimate, which had projected breakeven EPS of $0.00 for the quarter.
This divergence—missing on revenue but beating on adjusted profit—points directly to the aggressive cost-cutting measures management has implemented. The market's initial reaction appears cautiously positive, with the stock trading higher in pre-market activity following the release.
Strategic Restructuring Drives Financial Efficiency
The earnings press release heavily emphasizes the results of Amarin's "re-imagined operating model," initiated in mid-2025. The financial statements bear this out, showing a dramatic improvement in operating losses despite the top-line decline.
- Operating Loss: Narrowed to $6.3 million in Q4 2025 from a loss of $52.5 million in the prior-year period—an 88% improvement.
- Net Loss: Improved to $1.2 million, or $(0.00) per share, compared to a net loss of $48.6 million, or $(0.12) per share, in Q4 2024.
- Cost Reduction: Selling, general, and administrative (SG&A) expenses fell 46% year-over-year to $20.1 million. The company realized $31 million of an expected $70 million in total cost savings from its restructuring plan during the period.
CEO Aaron Berg stated the company has entered 2026 from "an improved position of market, operational, and financial strength," citing a leaner organization and a fully partnered international strategy.
Revenue Breakdown and Geographic Shift
The decline in total revenue is attributed to several transitional factors, most notably the company's strategic pivot in Europe.
- U.S. Revenue: Product revenue in the U.S. was $41.1 million, down 7% year-over-year, which the company attributes to a lower net selling price. Amarin maintains it held its leading market share for VASCEPA.
- International Transition: Revenue in Europe fell 42% to $2.3 million, and Rest-of-World revenue dropped 74% to $3.1 million. These declines were primarily due to the transition of European commercialization to partner Recordati S.p.A. and the absence of a large stocking order from a partner that occurred in Q4 2024. Moving forward, European revenue will consist solely of supply shipments to Recordati rather than direct sales.
- Licensing Growth: A bright spot was licensing and royalty revenue, which increased 20% to $2.7 million, driven by higher in-market sales from global partners.
Strong Balance Sheet and Forward Look
Amarin's financial position remains a key strength. The company ended the year with $302.6 million in cash and investments, a sequential and year-over-year increase, and carries no debt. CFO Peter Fishman noted the company achieved positive cash flow in Q4 "ahead of schedule" and is positioned to generate positive cash flow for the full year 2026.
The company did not provide specific quantitative financial guidance for 2026 in the press release. Analyst estimates currently project full-year 2026 sales of approximately $178.3 million and revenue for the first quarter of 2026 around $43.6 million. Investors will likely look for more detail on the trajectory of the U.S. business and the ramp-up of partner-driven international sales to gauge if the company can return to top-line growth while maintaining its new, leaner cost structure.
For a detailed view of historical earnings and future analyst estimates for Amarin, you can review the data here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
